Sanofi
SAN
Xếp hạng trong cổ phiếu
#225
Sanofi is a global healthcare enterprise dedicated to the research,... Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.
Giá cổ phiếu
$83.84
Vốn hóa thị trường
$100.45B
Thay đổi (1 ngày)
1.48%
Thay đổi (1 năm)
-16.74%
Quốc gia
FR
Giao dịch Sanofi (SAN)
Danh mục
Healthcare
Thu nhập của Sanofi (SAN)
Thu nhập trong 2026 TTM: 0
Theo báo cáo tài chính gần đây của Sanofi, lợi nhuận hiện tại của công ty là 0. Năm 2026, công ty đạt được lợi nhuận là 0, bằng với lợi nhuận năm 2026 là 0. Lợi nhuận hiển thị trên trang này là lợi nhuận trước lãi vay và thuế, hay còn gọi là EBIT.
Lịch sử thu nhập của Sanofi từ 2001 đến 2026
Thu nhập vào cuối mỗi năm
| Năm | Thu nhập | Thay đổi |
|---|---|---|
| 2025 | $7.06B | 0.44% |
| 2024 | $7.03B | 4.03% |
| 2023 | $6.76B | -36.93% |
| 2022 | $10.72B | 20.27% |
| 2021 | $8.91B | -48.24% |
| 2020 | $17.22B | 410.31% |
| 2019 | $3.37B | -40.13% |
| 2018 | $5.64B | -16.37% |
| 2017 | $6.74B | 10.21% |
| 2016 | $6.11B | 7.85% |
| 2015 | $5.67B | -16.42% |
| 2014 | $6.78B | 9.05% |
| 2013 | $6.22B | -23.52% |
| 2012 | $8.13B | 18.11% |
| 2011 | $6.89B | -8.02% |
| 2010 | $7.49B | -13.94% |
| 2009 | $8.70B | -34.25% |
| 2008 | $13.23B | 56.54% |
| 2007 | $8.45B | 35.27% |
| 2006 | $6.25B | 100.19% |
| 2005 | $3.12B | -224.94% |
| 2004 | $-2.50B | -163.40% |
| 2003 | $3.94B | 49.74% |
| 2002 | $2.63B | 38.31% |
| 2001 | $1.90B | 0.00% |
Thu nhập của các công ty hoặc đối thủ tương tự
| Công ty | Thu nhập | Chênh lệch thu nhập | Quốc gia |
|---|---|---|---|
| $33.60B | - |
US
|
|
| $17.74B | - |
US
|
|
| $8.70B | - |
US
|
|
| $5.95B | - |
US
|
|
| $21.39B | - |
CH
|
